The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53

Haematologica

Volumn 90, Issue 10, 2005, Pages 1435-1436

  Osuji, Nnenna C ^a   Del Giudice, Ilaria ^b   Matutes, Estella ^a   Wotherspoon, Andrew C ^c   Dearden, Claire ^a   Catovsky, Daniel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Dipartimento di Biotechnologie Cellulari ed Ematologia   (Italy)

^c Royal Marsden Hospital   (United Kingdom)

Author keywords

Alemtuzumab; CLL; Cytogenetics; p53

Indexed keywords

ALEMTUZUMAB; PROTEIN P53; RITUXIMAB; STEROID;

ADULT; AGED; ANOREXIA; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HERPES ZOSTER; HUMAN; INFECTION; LEUKOCYTE COUNT; LUNG INFECTION; MALE; NEUTROPENIA; REVIEW;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CHROMOSOME ABERRATIONS; GENE DELETION; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED;

EID: 27144437196     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9.
2. Valganon M, Giraldo P, Agirre X, Larrayoz MJ, Rubio-Martinez A, Rubio-Felix D, et al. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol 2005;129:53-9.
3. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
4. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-81.
5. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-765.
6. Stilgenbauer S, Winkler D, Kröber A. Subcutaneous campath-1H (alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2h Study of the German CLL Study Group (GCLLSG). Blood 2004;104:[Abstract#478].
7. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
8. Catovsky D, Richards S, Matutes E. Response to therapy and survival in CLL is influenced by genetic markers. Preliminary analysis from the LRF CLL4 Trial. Blood. 2004;104:[Abstract #13].
9. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347:452-3.
10. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004; 104:1428-34.